Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of BIIB100 in Adults with ALS
NCT03945279Phase 1Completed
- Sponsor
- Biogen
- Start
- May 2019
- Primary completion
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of BIIB100 in amyotrophic lateral sclerosis (ALS) (7 arms), sponsored by Biogen. Primary endpoint: Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs). Started May 2019; status: completed.
02
Drugs
BIIB100
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT03945279.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03945279.